For example, the PD-L1 IHC 22C3 pharmDx assay is approved by the Food and Drug Administration for selective PD-1/PD-L1-targeted immunotherapy (pembrolizumab) in non-small-cell lung cancer. Here, PDCD1 is linked to non-small cell lung carcinoma.